We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi | EU:SAN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.01% | 91.91 | 91.92 | 91.94 | 92.17 | 91.57 | 91.83 | 236,528 | 12:43:53 |
By Mauro Orru
Sanofi SA said Friday that net profit and sales for the first quarter of 2020 increased thanks to the strong performance of Dupixent, a monoclonal antibody used to treat diseases such as eczema and nasal polyps.
The French pharmaceutical major said first-quarter net profit rose to 1.68 billion euros ($1.82 billion) from EUR1.14 billion for the first quarter of 2019.
Business net income--a closely watched profit metric excluding some items--rose to EUR2.04 billion from EUR1.76 billion for the same period, with business earnings per share rising 15.6% at constant exchange rates to EUR1.63.
Sales jumped to EUR8.97 billion from EUR8.39 billion, Sanofi said.
The company said it still continues to expect 5% business EPS growth at constant exchange rates for the full year.
However, it anticipates the favorable coronavirus impact on sales and business EPS for the first quarter to be mainly offset during the second quarter.
"While the duration of the pandemic remains unknown at this point, I am confident Sanofi is well positioned to navigate these challenges and deliver on our commitment to patients," Chief Executive Paul Hudson said.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
April 24, 2020 02:12 ET (06:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions